About Corsair Phama
Corsair Phama is a company based in San Francisco (United States) founded in 2014. Corsair Phama has raised $23 million across 1 funding round from investors including Primavera Capital Group, New Rhein Healthcare Investors and Junson Capital. Corsair Phama offers products and services including Treprostinil Prodrug Patch. Corsair Phama operates in a competitive market with competitors including Actelion, scPharmaceuticals, Aerovate Therapeutics, Crossject and Centessa Pharmaceuticals, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Corsair Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23 M (USD)
in 1 rounds
-
Latest Funding Round
$23 M (USD), Series B
Sep 21, 2023
-
Investors
Primavera Capital Group
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Corsair Phama
Corsair Phama offers a comprehensive portfolio of products and services, including Treprostinil Prodrug Patch.
Delivers prodrug for consistent treprostinil levels in PAH treatment.
Funding Insights of Corsair Phama
Corsair Phama has successfully raised a total of $23M through 1 strategic funding round. The most recent funding activity was a Series B round of $23 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Corsair Phama
Corsair Phama has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Primavera Capital Group, New Rhein Healthcare Investors and Junson Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are focused on life sciences ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private equity investments in China are managed by Primavera.
|
Locked | Locked | Locked |
Investor details for Corsair Phama
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Corsair Phama
Investment portfolio details for Corsair Phama
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Corsair Phama
Detailed financials for Corsair Phama
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Corsair Phama Comparisons
Peer comparison for Corsair Phama
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Corsair Phama
Corsair Phama operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, scPharmaceuticals, Aerovate Therapeutics, Crossject and Centessa Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| Locked | Locked | Locked |
Therapeutic solutions for pulmonary arterial hypertension are developed.
|
|
| Locked | Locked | Locked |
Needle-free self-injectable drugs
|
|
| Locked | Locked | Locked |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
Detailed competitors of Corsair Phama
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Corsair Phama
Complete news archive for Corsair Phama
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Corsair Phama
Corsair Phama was founded in 2014 and raised its 1st funding round 9 years after it was founded.
Corsair Phama is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Bobby Singh is the current CEO of Corsair Phama.
Corsair Phama is a funded company, having raised a total of $23M across 1 funding round to date.
Developer of drugs for the treatemnt of cardiac diseases. It offers a prodrug of treprostinil which is delivered on a proprietary transdermal patch for the treatment of pulmonary arterial hypertension.
Corsair Phama's top competitors include scPharmaceuticals, Aerovate Therapeutics and Actelion.
Corsair Phama offers Treprostinil Prodrug Patch.
Corsair Phama has 5 investors. Key investors include Primavera Capital Group, New Rhein Healthcare Investors, Junson Capital, Midas Capital, and Plaisance Capital Management.